TRACON to Report Third Quarter 2018 Company Highlights and Financial Results on November 7, 2018
Conference call and webcast: | |
Date: | November 7, 2018 |
Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
Passcode: | 6170289 |
Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Company Contact: | Investor Contact: |
Mark Wiggins | Andrew McDonald |
Chief Business Officer | LifeSci Advisors LLC |
(858) 251-3492 | 646-597-6987 |
mwiggins@traconpharma.com | Andrew@lifesciadvisors.com |
Source: TRACON Pharmaceuticals, Inc.